CYTISINE is indicated for smoking cessation and reduction of nicotine cravings in smokers who are willing to stop smoking. The treatment goal of CYTISINE is the permanent cessation of the nicotine‑containing products use.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/. Adverse events should also be reported to Consilient Health (UK) Ltd, No. 1 Church Road, Richmond upon Thames, Surrey TW9 2QE UK or drugsafety@consilienthealth.com
By clicking CONTINUE you are confirming that you are a
Healthcare Professional registered in the UK.
Date of preparation January 2024 UK-CYT-101
Date of preparation March 2024 UK-CYT-114